Ratings for Lineage Cell Therapeutics (AMEX:LCTX) were provided by 7 analysts in the past three months, showcasing a mix of bullish and bearish perspectives. The table below provides a snapshot of ...
In recent news, several law firms announced that class action lawsuits have been filed against Lineage, Inc. following its July 2024 IPO, alleging the company made materially false or misleading ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback